The ENPICOM Platform seamlessly integrates AI, data management, and machine learning (ML) frameworks to foster collaboration among lab scientists, data scientists, and ML experts to drive innovation in biologics research.
ENPICOM secures additional funding to expand AI development and welcomes antibody discovery expert Dr. Colby Souders as a new investor.
ENPICOM partners with Erasmus Medical Center to develop nanobodies against cancer using their immune repertoire data analysis solutions.
Carterra and ENPICOM collaborate to streamline the analysis of sequencing and antibody screening data, focusing on identifying improved clinical-grade antibody candidates.
ENPICOM has secured additional funding to fuel international partnerships, enhance IGX Platform functionality, and introduce new generative AI solutions.
The new IGX-Track App expands the capabilities of the IGX Platform by adding seamless analysis of antibody panning campaigns.
Genovac, a leading CRO/CMO that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments, will utilize ENPICOM’s IGX Platform for antibody discovery workflows.
ENPICOM has secured funding from BOP Capital to support the growth of their unique SaaS platform for therapeutic antibody discovery.
Inno4vac is a new interdisciplinary project funded by the Innovative Medicines Initiative 2 that aims to foster health innovation by incorporating scientific and technological breakthrough from the academic and biotech sectors into industry.
The IGX Platform empowers researchers to accurately predict exposed liabilities for thousands of sequences at the same time using high-throughput structural modeling.
ENPICOM